Dr. Abdulhakim Al-Rawas is a Senior Consultant in Pediatric Hematology/Oncology at Sultan Qaboos University Hospital and President of the Omani Society of Hematology. A founding leader in regional hematology organizations, he trained at Queen’s University and SickKids, Toronto. He is deeply involved in undergraduate and postgraduate medical education in Oman and has authored 33 peer-reviewed publications in pediatric hematology and oncology.

Dr. Ahmad Alabdulkarim is a Specialist Haematologist at Jaber Alahmad Hospital, Kuwait. He earned his MD from the Royal College of Surgeons in Ireland and is board-certified by the Kuwait Board of Haematology. Dr. Alabdulkarim completed a Clinical Fellowship in Myeloproliferative Neoplasms and Myelodysplastic Syndromes at University College London Hospital and serves as a Clinical Tutor at the Kuwait Institute of Medical Specialisations, contributing to patient care and medical education.

Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton. He completed his training in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types. Prof. Davies specialises in the treatment of malignant lymphoma. He has a particular interest in the investigation of novel therapeutics applied to lymphoma. He has extensive experience in early phase trials, including leading first in man lymphoma studies all the way through to leading late phase studies. He also undertakes research activity in early diagnosis of cancer. He is Chair of the UK Lymphoma Research Network. He is Director of the Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults (TYA) and Clinical Lead for the Thames Valley and Wessex TYA Operational Delivery Network.

Anna Sureda, (MD, PhD) is nowadays the Head of the Clinical Hematology Department of Institut Català d’Oncologia – Hospitalet, Barcelona. She had previously been a Senior Consultant in Hospital de la Santa Creu i Sant Pau, Barcelona (from January 1991 to December 2010) and a Senior Consultant focused on lymphomas and hematopoietic stem cell transplantation (HSCT) at Addenbrookes–Cambridge University Hospital, UK (December 2010 – December 2012). Anna Sureda has focused her career on clinical investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation. Anna Sureda was appointed Chairperson of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) from March 2004 to March 2010 and Secretary of the same organization from March 2010 to March 2016. She was elected co-chair of the Lymphoma Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and has served the organization in this position from February 2015 to February 2019. She was subsequently appointed as member of a large non-US Transplant Center in the Advisory Committee of the CIBMTR (from February 2019). Anna Sureda has been President of the Spanish Society of Hematopoietic Stem Cell Transplantation and Cellular Therapy (GETH-TC) and, from March 2022 till March 2026, President of the EBMT. Anna Sureda is a regular reviewer of several peer reviewed journals (Blood, Annals of Oncology, Bone Marrow Transplantation, The Hematology Journal, The European Journal of Hematology y Annals of Hematology) and has co-authored more than 400 manuscripts.

Dr. Asma Al Olama is the President of the Emirates Society of Haematology and a Consultant Hematologist at Dubai Hospital. She has been actively involved in the field of hematology, particularly in the UAE, and has contributed to various initiatives and best practices in the area. Additionally, she serves as the Program Director of the Adult Hematology Fellowship program at Dubai Health.

No Bio Available

Professor Dirk Reinhardt is a pediatrician and internationally recognized specialist in pediatric hematology and oncology. His work focuses on acute myeloid leukemia, translational research, clinical trials, and improved care for seriously ill children. He led the AML-BFM Study Group for 16 years. Reinhardt has authored 374 peer-reviewed publications, holds an h-index of 77, and contributes extensively to international professional societies and collaborative networks. He was director and full-professor at the University Children’s Hospital Essen. Since 2025 he serves as CEO of the Leukemia Institute Frankfurt-Essen.

No Bio Available

Prof. Gina Zini, MD, PhD, is Professor of Hematology at Università Cattolica del Sacro Cuore and Consultant Hematologist at Policlinico A. Gemelli IRCCS in Rome, Italy. She is internationally recognized for her expertise in diagnostic hematology and serves as a member or chair of several prestigious international committees, including the European LeukemiaNet (ELN), International Council for Standardization in Haematology (ICSH), International Society for Laboratory Hematology (ISLH), World Health Organization (WHO), Clinical and Laboratory Standards Institute (CLSI), and the International Working Group on Myelodysplastic Syndromes (IWGM-MDS). Her research focuses on automated blood cell analysis, hematologic morphology, quality assurance and standardization, onco-hematology diagnostics, and the application of digital morphology and artificial intelligence in hematology education and practice. Prof. Zini has organized and taught more than 80 national and international diagnostic hematology courses, delivered over 1,000 invited lectures worldwide, and authored more than 225 peer-reviewed publications, with an H-index of 31.

Hanny Al-Samkari, M.D. is a classical hematologist and leading international clinical investigator in hemostasis, platelet disorders, and hemolytic anemias. His focus is on the development of novel therapeutics in hereditary hemorrhagic telangiectasia, immune thrombocytopenia, chemotherapy-induced thrombocytopenia and hemolytic anemia. He serves as global principal investigator for many ongoing studies in these areas.

Dr Raslan is a faculty member from NCI, Cairo university, full Professor since 2010. She joined KFSH-Dammam, 2007 and ongoing, Consultant Hematopathology, Created and implemented the Flowcytometry section, and have been the section head up to 2022, head of hematology section from 2019-2022. Dr. Raslan holding medical doctorate degree in Hematology and Oncological Hematology, she has Excellent experience in hematological malignancies, flowcytometry and teaching. She has leadership skills involving managing, and motivating teams to achieve their objectives. Maintaining high quality standards, she holds Six Sigma and TQM, and passed through multiple auditing from JCI, CAP and CPAHI. Dr Raslan Published 30 research papers in international and national Journals, 7 accepted abstracts, and has been speaker in many conferences, workshop, and advisory consultant on MPN, myeloma and leukemia committees, she attended more than 50 conferences and workshops.

Dr Hesham Elsabah received his M.B.ch.B degree from Bagdad University (Iraq) Completed the Arab Board in Internal Medicine in 2008 and the Hematology Fellowship program at NCCCR (2010-2013), he is a member of Royal college of physicians (MRCP). Currently, he serves as Senior Consultant of Hematology & BMT and his work is focus on multiple myeloma and acute leukemia.

No Bio Available

Transformational physician-executive and internationally recognized Hematologist, Medical Oncologist, and Bone Marrow Transplant leader with more than 20 years of progressive experience directing complex BMT, Cellular Therapy, and CAR-T programs at major academic cancer centers. Currently serves as Director, Adult Bone Marrow Transplantation & Cellular Therapy Program at King Hussein Cancer Center (KHCC) — the leading transplantation and oncology center in the Eastern Mediterranean Region. Demonstrated expertise in building high-performance multidisciplinary transplant teams, expanding allogeneic and autologous stem cell transplant services, pioneering academic CAR-T cell programs, achieving FACT accreditation, and driving clinical research excellence. Principal or Co-Investigator on more than 35 active national, regional, and international studies; author of more than 60 peer-reviewed publications in top journals including The Lancet, Blood, and Bone Marrow Transplantation. Secured EUR 2.5 million MILenARI EU grant for CAR-T manufacturing technology transfer across the Mediterranean.

Dr. Khalil Al Farsi is a Senior Consultant in Hematology and Bone Marrow Transplantation at the National Center for Hematology and BMT, University Medical City, Sultan Qaboos University, Muscat, Oman. His clinical expertise includes lymphoma, multiple myeloma, and autologous stem cell transplantation.

No Bio Available

No Bio Available

Dr. Mohamed Abuhaleeqa is an esteemed Consultant in Hematology, Leukemia, and Bone Marrow Transplant. With a robust medical journey that includes qualifications from prestigious institutions and a specialization in Hematology, he is a dedicated healthcare leader. Dr. Abuhaleeqa's commitment to knowledge sharing is evident through his mentoring of junior doctors and his role as the Program Director for the Hematology Fellowship Program in the UAE. His extensive qualifications include FRCPSC in Leukemia and Bone Marrow Transplant, Hematology, and Internal Medicine, and he is registered with the College of Physicians and Surgeons of British Columbia. He is an active participant in seminars, symposiums, and research in hematology and a member of respected medical associations, including ASBMT, EBMT and CIBMTR, underscoring his dedication to healthcare advancement in the UAE.

Dr. Mohammed Ibrahim Al Darwish is a Consultant in Pediatric Hematology and Oncology with over two decades of experience in pediatric medicine and inherited blood disorders. He earned his fellowship at King Faisal Specialist Hospital & Research Centre Riyadh. He also holds an Advanced Diploma in Healthcare Quality Management. Dr. Al Darwish has held several leadership positions, including Head of the Hematology Unit at Qatif Central Hospital, Deputy Medical Director of Prince Mohammed Bin Fahad Hospital for Inherited Blood Disorders, Deputy Director of the Pediatric Residency Program, and Head/Coordinator of Health Outreach Services. His clinical expertise includes benign hematology mainly inherited blood disorders . He is actively involved in clinical research, national guideline development, medical education, and quality improvement initiatives, and has contributed to numerous peer-reviewed publications and national healthcare projects.

No Bio Available

Dr. Mohamed Kharfan-Dabaja is a Professor of Medicine, vice-Chair of Hematology and Director of the Blood and Marrow Transplantation and Cellular Therapy Program at Mayo Clinic in Florida. He completed his fellowship in Hematology and Medical Oncology at The University of Miami, Jackson Memorial Hospital and Sylvester Comprehensive Cancer Center. His research focuses on CAR T-cell therapy in B-cell malignancies, hematopoietic cell transplantation, and evidence-based medicine research. He was the lead author of clinical practice recommendations on cellular immune therapies for treatment of chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular Therapy. He was the recipient of the 2025 King Hussein Lifetime Achievement Award for Cancer Research. He has more than 460 peer-reviewed publications and 24 book chapters.

Dr. Muna Altarshi is a Senior Consultant at the Royal Hospital, Muscat. She earned her MD from Sultan Qaboos University and completed Internal Medicine and Hematology training at McGill University, obtaining FRCPC and American Board certifications. She completed a Bone Marrow Transplant fellowship at Princess Margaret Cancer Centre, University of Toronto. Her practice focuses on lymphoma, plasma cell myeloma, and autologous stem cell transplantation. She is Associate Program Director at the Oman Medical Specialty Board and Treasurer of the Omani Society of Hematology.

Prof. Murtadha Al-Khabori is a Professor of Hematology at Sultan Qaboos University and Senior Consultant Hematologist at Sultan Qaboos University Hospital, Oman. He leads the Hematology Department and plays a key role in the national bone marrow transplant program. He completed advanced hematology and stem cell transplant training at Princess Margaret Hospital and research training at McMaster University, Canada. Prof. Al-Khabori has authored over 100 peer-reviewed publications and serves as an Associate Editor of the Oman Medical Journal. His clinical and research interests focus on acute leukemia, myeloproliferative neoplasms, and hematopoietic stem cell transplantation.

Dr. Naval Daver is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. He completed his medical school from Grant Medical College and Sir J group of Hospitals Mumbai, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in AML and Myelofibrosis and is principal investigator on >25 ongoing institutional, national and international clinical trials clinical trials: Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease. If you have a bone marrow failure disease, you may want to consider taking part in a clinical trial, also called a research study. Understanding Clinical Trials Clinical…in these diseases.

No Bio Available

Noemi Puig, MD, PhD earned her medical degree from the Universidad Complutense in Madrid and she completed her residency in Internal Medicine and Hematology at the University Hospital La Fe in Valencia, Spain. She completed a 3-year fellowship in Lymphoma, Myeloma and Autologous Stem Cell Transplantation at the Princess Margaret Hospital in the University of Toronto, in Toronto, Canada. She earned a doctoral degree at the Medicine Department of the University of Salamanca, in Spain, with a thesis entitled “Optimization and Critical Analysis of Minimal Residual Disease Monitoring with ASO RQ-PCR in Patients with Multiple Myeloma and Comparison with Multiparameter Flow Cytometry”. Dr. Puig currently serves as a Consultant Physician at the Hematology Department in the University Hospital of Salamanca. She also works in the Flow Cytometry Laboratory of the University Hospital of Salamanca, where she is responsible for the studies developed by the Spanish Myeloma Group. Dr. Puig is a member of the Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) and the Spanish Myeloma Group (GEM) as well as of the EuroFlow Group. Dr. Puig´s main research interests include the role of multiparameter flow cytometry and of mass spectrometry in diagnosis, risk stratification and minimal residual disease monitoring in patients with monoclonal gammopathies. She is an author or co-author in several research articles, reviews and book chapters.

Dr. Prashant Tembhare, is a Clinician Scientist and Professor in Department of Hematopathology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Center, Navi Mumbai. He obtained an MD in Pathology and a Hematopathology fellowship in Tata Memorial Centre. Then he completed a post-doctoral fellowship in Flow Cytometry Laboratory, CCR-NCI, NIH, Bethesda, USA. He has been working at TMC since 2013. Presently he is a Treasurer of The Cytometry Society-India. He has published more than 100 research articles with more than 7862 citations with H-index of 27. He has written flow cytometry chapters in six international textbooks. He has received many national and international awards. He is representing India in international collaborations such as International Collaboration in Cancer Reporting (ICCR) for Multiple myeloma and ELN-DAVID for AML MRD and one of the members of ELN group for AMLMRD by spectral flow cytometry. He has authored 13 topics in the 5th WHO book for Hematolymphoid neoplasm. He is on the editorial board and reviewer for many national and international journals including Clinical Cytometry B. His expertise includes the flow cytometric assessment of high-sensitivity MRD monitoring in B-ALL, T-ALL, and Myeloma, 16-color MRD in AML, CLL and T-NHL. He also works on flow cytometric analysis in MDS, CMML, B and T-NHL, DNA ploidy evaluation and Pediatric round cell tumor determination. He has also developed 16-color deep immune cell profile monitoring, CAR-T-cell monitoring assay and antiCD19 B-ALL MRD assay. Currently he is working on 22-color AML MRD using full Spectrum flow cytometry and Ultrasensitive Blood based MRD assessment in multiple myeloma.

No Bio Available

No Bio Available

No Bio Available

No Bio Available

Dr. Zaid Abdel Rahman is a hematologist, hematopoietic stem cell transplant and cellular therapies physician whose research focuses on improving access to advanced diagnostics, therapeutics and cellular therapies in resource-limited settings. He received his training at Henry Ford Hospital, Mayo clinic and the University of Texas MD Anderson Cancer Center. His current work centers on the clinical implementation of novel immunotherapies, particularly CAR-T cell therapies, through regional and international partnerships, with an emphasis on point-of-care manufacturing. His research portfolio includes multiple studies evaluating outcomes in leukemias, clinical applications of CAR-T cell therapy, and innovative approaches to autologous and allogeneic transplantation adapted to constrained healthcare environments. His broader academic interests include transplant complications, ethical dimensions of genomic testing, and rare hematologic disorders.

Dr. AI-Shaibani completed his clinical fellowship in Allogeneic Transplantation within the Hans Messner Allogenic Transplant Program, Canada as well as additional fellowship training in both the Leukemia and Lymphoma Programs at the Princess Margaret Cancer Centre. In 2018, Dr. Al-Shaibani completed the Master Teacher Program at the University of Toronto. Dr. Al-Shaibani is appointed as an Assistant Professor in the Department of Medicine, University of Toronto.